Skip to main content
Tag

biotech commercialization Archives - BioHealth Innovation

From Bavaria to BioHealth: BioM’s Ralf Huss on Building a Global Biotech Cluster

By BioTalk with Rich Bendis Podcast, News

In this episode of BioTalk with Rich Bendis, Ralf Huss, MD, PhD, Managing Director and CEO of BioM Biotech Cluster Development GmbH and spokesperson for the Bavarian Biotechnology Cluster, joins the conversation to discuss Bavaria’s biotechnology ecosystem and BioM’s role in moving science toward commercialization.

Ralf introduces BioM, the organization supporting biotech development in Munich and Bavaria for nearly 30 years, and shares how the cluster helps founders move from research ideas to company formation. The conversation touches on mentoring, boot camps, investor connections, entrepreneur-in-residence support, startup training, and physical incubation.

Listen now via your favorite podcast platform:
Apple: https://apple.co/4r9uzV7
Spotify: https://bit.ly/4cJvxS3
iHeart: https://ihr.fm/4gQHFDh
Amazon: https://amzn.to/4r9TtDW
YouTube: https://bit.ly/4r9b1Ah
TuneIn: https://bit.ly/3USac2L

Rich and Ralf also discuss the MAxL incubator, the m4 Award, and BioM’s work with more than 250 startups. Ralf shares his perspective on what early-stage teams need most, why strong science alone is not enough, and how business leadership, IP, financing, market need, and the right commercialization path all play a role.

The episode also explores emerging opportunities in biotech and medicine, including AI, digital medicine, quantum computing, nanotechnology, regenerative medicine, tech bio, and the growing convergence of biology, engineering, and advanced technologies. Ralf also discusses why international collaboration matters for regional biotech clusters and how Bavarian companies are thinking about U.S. partnerships, investors, market access, and connections to ecosystems like the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Ralf Huss, MD, PhD, is a physician-scientist, surgical pathologist, biotechnology executive, entrepreneur, and innovation leader with more than three decades of experience across academia, pharmaceutical research, biotechnology, digital pathology, regenerative medicine, and artificial intelligence in healthcare. He currently serves as Managing Director and CEO of BioM, the organization responsible for the development of the Bavarian Biotechnology Cluster, one of Europe’s leading life science ecosystems. Throughout his career, he has held leadership positions in multinational pharmaceutical companies, venture-backed biotechnology firms, international academic research and medical centers, and innovation organizations, with a particular focus on translational medicine, cell and gene therapy, digital medicine, and AI-driven diagnostics. He has been awarded numerous honors and published more than 180 peer-reviewed articles, books, and book chapters.

BHI EIR Insights: 7 Tactics to Optimize Launch Messaging – Part VI

By EIR Insights, News

by Jonathan Kay, MPP, Managing Partner, Health Market Experts & BioHealth Innovation, Inc. Entrepreneur-in-Residence

To recap, the first 5 posts of our series covered:

  1. Test, Don’t Guess: Adopt a data-driven mindset about messaging impact
  2. Know Your Stakeholders: Avoid a one-size-fits-all approach
  3. Listen First: What are  your stakeholders saying and how?
  4. Message Anatomy: Ensure messages get the job done
  5. Measuring Success: Define metrics of success upfront

Insight 6: Just Start

It’s true we want to pursue all 5 tactics above. But that doesn’t mean we always can.  Sometimes clients or would-be clients insist:

  • Time is too limited, so they can’t test
  • The target audience is rare or ultra rare, so they can’t test

🛑 Hold on! Don’t skip testing even in these situations. As the saying goes, Don’t let perfect be the enemy of the good.(That’s typically attributed to surgeons!🥼)

Real-world problems require real-world problem-solving. To know in advance how well your messages will perform, ask real-world stakeholders. Even if time is extremely limited. Even if audiences seem too hard-to-reach. (We can help you in both cases. While we encourage clients to have a launch runway and notify us in advance, typically we can line up test audiences in a day or two, or faster!)

Testing messages BEFORE launch can improve early uptake 📈, increase commercial success, and save time and budget later. It can help you avoid unnecessary stress.

✅ Rather than skip testing, “just start” testing by modifying the ideal and going with what is realistic. Here are a few ideas:

  • Fewer interviews
  • Shorter survey
  • Leverage Gen AI (more to come in Tactic #7)
  • Plan ahead: put message testing in your launch plan

When a client was preparing to launch a genetic marker for a rare disease, they approached us to test physician ad concepts and messages. They faced two familiar constraints in biotech launches:

  1. Limited time
  2. A small, hard-to-reach physician population

One more traditional approach might have been to test messages → share feedback with client and creative agency → agency modifies concepts → ideally we test again to optimize. Instead, we compressed the process and reduced the timeline by days, possibly a week. (How great would it be to save a week when getting ready for launch?)

How did we do that?

  • We reduced the number of stakeholder interviews.
  • We prioritized metrics like stopping power, visceral response, clinical credibility
  • Importantly, we invited the agency into the testing process.

Bringing the agency in allowed for agile development. As the interviews progressed, the concepts evolved, and we moved closer and closer to optimal with each next test.

The results were telling, actionable, and valuable even with a small sample. We confirmed a key hypothesis, which added confidence to the commercial strategy. We also revealed confusing language about the biomarker that we easily fixed to avoid encountering post-launch confusion, questions, and delayed product adoption.

The key takeaway: When launching a business or a brand or a campaign, perfect conditions are rare. But even limited testing can uncover powerful insights, reduce risk, and strengthen confidence before your message reaches the market.

If your organization is preparing to launch a new business or brand, connect with us (message me on LinkedIn) or visit https://www.healthmarketexperts.com/ to learn more about how we can help you with messaging and commercial strategy to set your business and brand on a path of success.

Written by a human. This post expands on content I previously wrote as a blog at Catalant and delivered in guest lectures at Rutgers Business School.

Visit https://www.linkedin.com/in/jonathan-kay-healthcare/ to connect with Jon on LinkedIn.

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.